Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bulent Yilmaz

Showing results (71-80 of 78) with videos related to

Pageof 8
Sort By:
You have reached the last page of results.This site can display upto 78 results.
Journal of Immunotherapy and Precision Oncology|June 6, 2022
Role of Abdominal and Pelvic CT Scans in Diagnosis of Patients with Immunotherapy-Induced ColitisJuan Ibarra Rovira, Selvi Thirumurthi, Melissa Taggart, et al.
Cancer Medicine|February 24, 2024
Phase I study of sapanisertib (CB-228/TAK-228/MLN0128) in combination with ziv-aflibercept in patients with advanced solid tumorsNiamh Coleman, Bettzy Stephen, Siqing Fu, et al.
Cancer|May 2, 2023
Safety, tolerability, and clinical activity of selinexor in combination with pembrolizumab in treatment of metastatic non-small cell lung cancerMehmet Altan, Janet Tu, Denái R Milton, et al.
Journal of Immunotherapy and Precision Oncology|November 11, 2024
A Phase Ib Study of Selinexor in Combination with Pembrolizumab in Patients with Metastatic MelanomaMohamed A Gouda, Bettzy Stephen, Yanyan Tian, et al.
Gynecologic Oncology|November 24, 2022
Selinexor in combination with weekly paclitaxel in patients with metastatic solid tumors: Results of an open label, single-center, multi-arm phase 1b study with expansion phase in ovarian cancerShannon N Westin, Siqing Fu, Apostolia Tsimberidou, et al.
The Oncologist|March 23, 2023
Safety and Efficacy of Immune Checkpoint Inhibitors in Patients with Cancer and Viral Hepatitis: The MD Anderson Cancer Center ExperienceMirella Nardo, Bulent Yilmaz, Blessie Elizabeth Nelson, et al.
Cancer Medicine|February 13, 2025
A Phase IB Trial of Selinexor in Combination With Immune Checkpoint Blockade in Patients With Advanced Renal Cell CarcinomaOmar Alhalabi, Mohamed A Gouda, Denái R Milton, et al.
Cancer|April 5, 2023
Phase 1b study of combined selinexor and eribulin for the treatment of advanced solid tumors and triple-negative breast cancerBlessie Elizabeth Nelson, Sadia Saleem, Senthil Damodaran, et al.
Pageof 8

Showing results (71-80 of 78) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 78 results.
Journal of Immunotherapy and Precision Oncology|June 6, 2022
Role of Abdominal and Pelvic CT Scans in Diagnosis of Patients with Immunotherapy-Induced ColitisJuan Ibarra Rovira, Selvi Thirumurthi, Melissa Taggart, et al.
Cancer Medicine|February 24, 2024
Phase I study of sapanisertib (CB-228/TAK-228/MLN0128) in combination with ziv-aflibercept in patients with advanced solid tumorsNiamh Coleman, Bettzy Stephen, Siqing Fu, et al.
Cancer|May 2, 2023
Safety, tolerability, and clinical activity of selinexor in combination with pembrolizumab in treatment of metastatic non-small cell lung cancerMehmet Altan, Janet Tu, Denái R Milton, et al.
Journal of Immunotherapy and Precision Oncology|November 11, 2024
A Phase Ib Study of Selinexor in Combination with Pembrolizumab in Patients with Metastatic MelanomaMohamed A Gouda, Bettzy Stephen, Yanyan Tian, et al.
Gynecologic Oncology|November 24, 2022
Selinexor in combination with weekly paclitaxel in patients with metastatic solid tumors: Results of an open label, single-center, multi-arm phase 1b study with expansion phase in ovarian cancerShannon N Westin, Siqing Fu, Apostolia Tsimberidou, et al.
The Oncologist|March 23, 2023
Safety and Efficacy of Immune Checkpoint Inhibitors in Patients with Cancer and Viral Hepatitis: The MD Anderson Cancer Center ExperienceMirella Nardo, Bulent Yilmaz, Blessie Elizabeth Nelson, et al.
Cancer Medicine|February 13, 2025
A Phase IB Trial of Selinexor in Combination With Immune Checkpoint Blockade in Patients With Advanced Renal Cell CarcinomaOmar Alhalabi, Mohamed A Gouda, Denái R Milton, et al.
Cancer|April 5, 2023
Phase 1b study of combined selinexor and eribulin for the treatment of advanced solid tumors and triple-negative breast cancerBlessie Elizabeth Nelson, Sadia Saleem, Senthil Damodaran, et al.
Pageof 8